Michael Davis
Lawyers

Filters
Charles River Laboratories acquisition of Vigene Biosciences
We are advising Charles River on the acquisition
Lightyear Capital to sell Therapy Brands to KKR
We advised Lightyear Capital on the sale
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
RTL Group $1.17 billion sale of SpotX to Magnite
We are advising RTL Group on the sale of its U.S. ad-tech company
Bertelsmann $2.175 billion acquisition of Simon & Schuster
Davis Polk is advising Bertelsmann on the $2.175 billion acquisition by its global trade book publishing group, Penguin Random House, of Simon & Schuster from ViacomCBS. The transaction…
Traton $3.7 billion acquisition of Navistar International
Davis Polk is advising Traton SE on its $3.7 billion acquisition of Navistar International Corp. Traton, which already owns an approximately 16.7% stake in Navistar, will acquire all…
Lightyear Capital & Ontario Teachers’ Pension acquisition of Allworth Financial
Davis Polk is advising Lightyear Capital and Ontario Teachers’ Pension Plan Board on their acquisition of wealth management firm Allworth Financial from private equity funds managed by…
American Well $853 million IPO and NYSE listing
Davis Polk advised American Well Corporation (“Amwell”) in connection with its initial public offering of 47,405,555 shares of Class A common stock for approximately $853 million in total…
American Well strategic partnership with Google Cloud
Davis Polk is advising Amwell on its agreement to form a multi-year, strategic partnership with Google Cloud to deliver transformative telehealth solutions across the global healthcare…
Bristol Myers Squibb acquisition of Forbius
Davis Polk is advising Bristol Myers Squibb on its acquisition of Forbius. The transaction includes an upfront payment and future success-based milestone payments. The transaction is…